Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated:  7/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Enrolling
Updated: 7/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Prospective Measurement of Post-Treatment Lymphedema
Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma
Status: Enrolling
Updated:  7/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Prospective Measurement of Post-Treatment Lymphedema
Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma
Status: Enrolling
Updated: 7/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma
Status: Enrolling
Updated:  7/28/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma
Status: Enrolling
Updated: 7/28/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma
Status: Enrolling
Updated:  7/28/2016
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma
Status: Enrolling
Updated: 7/28/2016
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Children's Hospital of LA
mi
from
Los Angeles, CA
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Children's Hospital of LA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
James Whitcomb Riley Hospital for Children
mi
from
Indianapolis, IN
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
James Whitcomb Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
The Mayo Clinic
mi
from
Rochester, MN
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
University of Pittsburgh Medical Center Cancer Center
mi
from
Pittsburgh, PA
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
University of Pittsburgh Medical Center Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated:  7/28/2016
Local Institution
mi
from
Gent,
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Status: Enrolling
Updated: 7/28/2016
Local Institution
mi
from
Gent,
Click here to add this to my saved trials
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Sarasota, FL
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated:  8/1/2016
mi
from
Camperdown,
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status: Enrolling
Updated: 8/1/2016
mi
from
Camperdown,
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Irvine, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Lodi, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Lodi, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Loma Linda, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Newport Beach, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Palo Alto, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials